Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Abu-Raddad, L. J., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., ... Bertollini, R. (2021). Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of Travel Medicine, 28(7). https://doi.org/10.1093/jtm/taab083

Published in:
Journal of Travel Medicine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2021 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback
Rapid Communication

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Laith J. Abu-Raddad, PhD, Hiam Chemaitelly, MSc, Hadi M. Yassine, PhD, Fatiha M. Benslimane, PhD, Hebah A. Al Khatib, PhD, Patrick Tang, MD, PhD, Joel A. Malek, PhD, Peter Coyle, MD, Houssein H. Ayoub, PhD, Zaina Al Kanaani, PhD, Einas Al Kuwari, MD, Andrew Jeremijenko, MD, Anvar Hassan Kaleeckal, MSc, Ali Nizar Latif, MD, Riyazuddin Mohammad Shaik, MSc, Hanan F. Abdul Rahim, PhD, Gheyath K. Nasrallah, PhD, Mohamed Ghaith Al Kuwari, MD, Hamad Eid Al Romaihi, MD, Mohamed H. Al-Thani, MD, Abdullatif Al Khal, MD, Adeel A. Butt, MD, and Roberto Bertollini, MD MPH

1Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar, 2World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine—Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar, 3Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA, 4Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar, 5Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar, 6Department of Pathology, Sidra Medicine, Doha, Qatar, 7Genomics Laboratory, Weill Cornell Medicine–Qatar, Cornell University, Doha, Qatar, 8Department of Genetic Medicine, Weill Cornell Medicine–Qatar, Cornell University, Doha, Qatar, 9Hamad Medical Corporation, Doha, Qatar, 10Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, UK, 11Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar, 12College of Health Sciences, QU Health, Qatar University, Doha, Qatar, 13Primary Health Care Corporation, Doha, Qatar and 14Ministry of Public Health, Doha, Qatar

*To whom correspondence should be addressed. Email: lja2002@qatar-med.cornell.edu

Submitted 24 May 2021; Revised 25 May 2021; Editorial Decision 26 May 2021; Accepted 26 May 2021

Key words: SARS-CoV-2, alpha variant, beta variant, delta variant, B1.617.2, B1.1.7

Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of people in the shortest time, in situations of limited vaccine supplies and high incidence, could avert more disease cases, hospitalizations and deaths than the current protocol of a second dose shortly after the first dose. 

BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Qatar was recently reported with focus on individuals who completed 14 days after the second dose. Here, we provide a follow-up analysis of how vaccine protection develops week-by-week after the first dose.

Data for SARS-CoV-2 were extracted from Qatar’s nationwide digital-health information platform. The platform hosts the national centralized SARS-CoV-2 databases that captured all vaccination records, polymerase chain reaction (PCR) testing, and COVID-19 hospitalizations and deaths since epidemic start. The study was conducted from 1 February to 31 March 2021, the period of rapid mass vaccination scale-up. Vaccine effectiveness was estimated using the test-negative case-control study design. Cases and controls were matched one-to-one by age, sex,
Figure 1. The messenger RNA vaccine BNT162b2 (Pfizer-BioNTech) effectiveness against infection and against disease in the weeks following the first dose. Error bars indicate the 95% confidence intervals for vaccine effectiveness estimates.
Table 1. The messenger RNA vaccine BNT162b2 (Pfizer-BioNTech) effectiveness against infection and against disease in the weeks following vaccination with the first dose

|                           | 1–7 days after dose 1 | 8–14 days after dose 1 |
|---------------------------|-----------------------|------------------------|
|                           | Cases (PCR positive)  | Controls (PCR negative) | Effectiveness in % (95% CI)<sup>a</sup> | Cases (PCR positive)  | Controls (PCR negative) | Effectiveness in % (95% CI)<sup>a</sup> |
|                           | Vaccinated            | Unvaccinated           |                                 | Vaccinated            | Unvaccinated           |                                 |
| Effectiveness against infection |                       |                        |                                 |                       |                        |                                 |
| Any infection with the B.1.1.7 variant<sup>b</sup> | 279                   | 17 262                | 262 309                        | 17 232                | 0.0 (0.0–15.8)          |                                 |
| Any infection with the B.1.351 variant<sup>c</sup> | 276                   | 19 071                | 276 19 071                      | 276 19 071            | 0.0 (0.0–72.8)          |                                 |
| Effectiveness against disease |                       |                        |                                 |                       |                        |                                 |
| Any severe, critical, or fatal disease with the B.1.1.7 variant<sup>d</sup> | 12                    | 431                   | 19 424                          | 37.9 (0.0–72.8)        |                                 |
| Any severe, critical, or fatal disease with the B.1.351 variant<sup>e</sup> | 16                    | 321                   | 6 331                           | 0.0 (0.0–0.0)          |                                 |
| Any severe, critical, or fatal disease with any SARS-CoV-2 infection<sup>f</sup> | 49                    | 1807                  | 44 1812                         | 0.0 (0.0–27.6)         |                                 |
| 15–21 days after dose 1 |                       |                        |                                 |                       |                        |                                 |
| Effectiveness against infection |                       |                        |                                 |                       |                        |                                 |
| Any infection with the B.1.1.7 variant<sup>b</sup> | 148                   | 17 380                | 422 17 106                       | 65.5 (58.2–71.5)       |                                 |
| Any infection with the B.1.351 variant<sup>c</sup> | 338                   | 19 400                | 623 19 115                       | 46.5 (38.7–53.3)       |                                 |
| Effectiveness against disease |                       |                        |                                 |                       |                        |                                 |
| Any severe, critical, or fatal disease with the B.1.1.7 variant<sup>d</sup> | 7                     | 434                   | 24 417                          | 72.0 (32.0–90.0)       |                                 |
| Any severe, critical, or fatal disease with the B.1.351 variant<sup>e</sup> | 9                     | 336                   | 20 325                          | 56.5 (0.0–82.8)        |                                 |
| Any severe, critical, or fatal disease with any SARS-CoV-2 infection<sup>f</sup> | 23                    | 1845                  | 83 1785                         | 73.2 (56.8–84.0)       |                                 |
| ≥14 days after second dose |                       |                        |                                 |                       |                        |                                 |
| Effectiveness against infection |                       |                        |                                 |                       |                        |                                 |
| Any infection with the B.1.1.7 variant<sup>b</sup> |                       |                       |                                 |                       |                        |                                 |
| Any infection with the B.1.351 variant<sup>c</sup> |                       |                       |                                 |                       |                        |                                 |
| Effectiveness against disease |                       |                        |                                 |                       |                        |                                 |
| Any severe, critical, or fatal disease with the B.1.1.7 variant<sup>d</sup> |                       |                       |                                 |                       |                        |                                 |
| Any severe, critical, or fatal disease with the B.1.351 variant<sup>e</sup> |                       |                       |                                 |                       |                        |                                 |
| Any severe, critical, or fatal disease with any SARS-CoV-2 infection<sup>f</sup> |                       |                       |                                 |                       |                        |                                 |

<sup>a</sup>Vaccine effectiveness was estimated using the test-negative, case–control study design. Cases and controls were matched one-to-one by age, sex, nationality, and reason for PCR testing. Vaccine effectiveness is given by

\[
\text{Vaccine effectiveness} = \frac{1 - \frac{\text{vaccinated among cases}}{\text{unvaccinated among controls}}}{\frac{\text{vaccinated among controls}}{\text{unvaccinated among cases}}}
\]

<sup>b</sup>Any B.1.1.7 PCR-confirmed infection. A B.1.1.7 infection is proxied as an S-gene 'target failure' case using the TaqPath COVID-19 Combo Kit platform (Thermo Fisher Scientific, USA), applying the criterion of PCR cycle threshold value \( \leq 30 \) for both the N and ORF1ab genes, but a negative outcome for the S-gene. The median date of vaccination was March 1 2021 for the cases and February 28 2021 for their matched controls.

<sup>c</sup>Any B.1.351 PCR-confirmed infection. With only B.1.351 and B.1.1.7 cases identified in the viral genome sequencing after 7 March 2021, a B.1.351 infection is proxied as the complement of the B.1.1.7 criterion, that is any infection with a Ct value \( \leq 30 \) for the N, ORF1ab and S genes between March 8 and 31 2021. The median date of vaccination was March 7 2021 for the cases and March 1 2021 for their matched controls.

<sup>d</sup>Any B.1.1.7 PCR-confirmed infection that led to severe, critical or fatal disease. Severe disease, critical disease and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity and COVID-19-related death.

<sup>e</sup>Any B.1.351 PCR-confirmed infection that led to severe, critical or fatal disease. Severe disease, critical disease and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity and COVID-19-related death.

<sup>f</sup>Any PCR-confirmed infection that led to severe, critical or fatal disease. With the dominance of both B.1.1.7 and B.1.351 variants during the study period, this effectiveness is a combined measure against both of these variants. Severe disease, critical disease and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity and COVID-19-related death.
nationality and reason for PCR testing. Effectiveness was estimated against documented infection with the B.1.1.7 or B.1.351 variants, as well as against severe, critical or fatal disease due to any SARS-CoV-2 infection. Classification of COVID-19 case severity (acute-care hospitalizations),\(^4\) criticality (ICU hospitalizations)\(^3\) and fatality\(^4\) followed the World Health Organization guidelines. Further details on study methods can be found in our previous publication.\(^4\)

Between 1 February and 31 March 2021, 333,764 individuals received at least one BNT162b2 vaccine dose, of whom 250,619 completed two doses. Two-thirds (60.8\%) of those vaccinated were men, and the median age was 40 years. Median time elapsed between the first and second doses was 21 days, and 98.4\% of individuals received their second dose \(\leq 25\) days after the first dose. Effectiveness against infection with B.1.1.7 or B.1.351 was negligible for 2 weeks after the first dose (Figure 1). Effectiveness increased rapidly during the third week to 65.5\% (95\% CI: 58.2–71.5) against B.1.1.7 and 46.5\% (95\% CI: 38.7–53.3) against B.1.351 (Table 1). Eventually, \(\geq 14\) days after the second dose, effectiveness reached 89.5\% (95\% CI: 85.9–92.3) against B.1.1.7 and 75.0\% (95\% CI: 70.5–78.9) against B.1.351.

Effectiveness against severe, critical or fatal disease (predominantly due to B.1.1.7 and B.1.351)\(^1\) was negligible during the first week, reached 26.4\% (95\% CI: 0.0–49.9) in the second week, and grew to 73.2\% (95\% CI: 56.8–84.0) in the third week (Table 1). Eventually, \(\geq 14\) days after the second dose, effectiveness reached 97.4\% (95\% CI: 92.2–99.5).

Development of protection against infection and disease accelerated in the third week after the first dose, right before the second dose, reaching nearly 75\% of the value attained \(\geq 14\) days after the second dose. Protection increased most rapidly against hospitalization and death and slowest against B.1.351 infection. While protection of one dose beyond 21 days could not be assessed, and existing protocol requires a second dose for optimal protection, these findings support the strategy of delaying the second dose to vaccinate the largest number of people in the shortest time, in situations of limited vaccine supplies and high incidence, given the substantial protection achieved after only one dose. In areas where B.1.351 is at high incidence, delivering the second vaccine dose at 3–6 weeks after the first dose may be considered with the lower and slower build-up of protection against this variant.

### Key Points
- This population-based study documents BNT162b2 vaccine protection week-by-week after the first dose.
- 75\% of protection against infection and disease is reached 15–21 days after the first dose.
- Protection increased most rapidly against hospitalization and death and slowest against B.1.351 infection.
- While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccine dose in situations of limited vaccine supplies and high incidence.

### Authors’ contributions
L.J.A. co-conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. A.B. and R.B. co-conceived and co-designed the study. H.C. co-designed the study, performed the statistical analyses and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

### Acknowledgements
We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation and the Qatar Biobank for their diligent efforts and contributions to make this study possible.

### Funding
This work was supported by the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as by the Ministry of Public Health and Hamad Medical Corporation. Viral genome sequencing was also supported by the Qatar Genome Programme. Statements made herein are solely the responsibility of the authors.

### Conflict of interest
Dr Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, authors declare no conflicts of interest.

### Ethical approval
This study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent.

### References
1. Abu-Raddad LJ, Chemaitelly H, Butt AA. National Study Group for C-V. Effectiveness of the bnt162b2 covid-19 vaccine against the b.1.1.7 and b.1.351 variants. N Engl J Med 2021. doi: 10.1056/NEJMc2104974.
2. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31(17):2165–8.
3. World Health Organization. Covid-19 clinical management: living guidance. Available from: https://www.Who.Int/publications/i/item/who-2019-ncov-clinical-2021-1 (15 May 2021, date last accessed).
4. World Health Organization. International guidelines for certification and classification (coding) of covid-19 as cause of death. Available from: https://www.Who.Int/classifications/icd/guidelines_CAUSE_of_death_covid-19-20200420-en.Pdf?Uat=1. Document number: Who/hsq/dd/DNA/cat (15 May 2021, date last accessed).
5. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Data on Randomly Collected Samples Between February 1–April 30, 2021. Data available upon request, 2021.